Fort Lee, New Jersey, Oct. 6, 2014 (GLOBE NEWSWIRE) -- Herborium® Group, Inc.(OTC Pink: HBRM), www.Herborium.com, a Botanical Therapeutics® Company and the provider of unique all botanical medicines (Botanical Therapeutics®) has presented the Company's opportunities and its unique all botanical treatments at the 7th Annual "Life Science Stakeholders Summit" on Thursday, October 2nd 2014. The Conference was focused on latest innovations and disruptive technologies and their impact on healthcare, and was sponsored by Livingston Securities LLC., and BakerHostetler LLP.
Livingston Securities is a licensed Broker Dealer with a focus on innovative microcap companies that are commercializing and/or impacted by scientific advances in the emerging fields of life science, nanotechnology and other leading sectors of the American economy.
BakerHostetler, one of the nation's largest law firms has an interest in innovations and their role in global competitiveness, and is an expert in laws and regulations that help clients fuel their strategic growth including Intellectual Property Laws and FDA Regulations.
"The participation in the Conference chaired by Mostafa Analoui, Ph.D., Head of Healthcare and Life Sciences at The Livingston Group (New York, NY) previously the Senior Director at Pfizer Global Research and Development, was by invitation only.
Herborium's well received presentation at the Conference is another step in recognizing Herborium's value proposition and a part of the Company's plan to introduce its opportunity, and its unique products to a broad spectrum of potential strategic institutional partners and investors". Commented Dr. Agnes P. Olszewski, CEO and Chairman of Herborium Group, Inc.
There is a rising interest in Botanical Therapeutics® among consumers as well as the financial, medical and nutraceutical communities that serve as a solid foundation for the company's promising future.
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics® company that develops, license and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, prostate health, women's health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, diabetes, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. For more information, please visit www.herborium.com, and www.acnease.com.
Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Sunrise Consulting Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.